Halozyme Therapeutics Inc (MEX:HALO) Stock Price, Trades & News

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.15
Equity-to-Asset	0.08
Debt-to-Equity	9.77
Debt-to-EBITDA	3.44
Interest Coverage	44.25
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.91	Distress Grey Safe
Beneish M-Score	-1.9	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	33.9
	3-Year EBITDA Growth Rate	27.3
	3-Year EPS without NRI Growth Rate	23.4
	3-Year FCF Growth Rate	19.8
	3-Year Book Growth Rate	-30.9
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	36.1
	Future 3-5Y Total Revenue Growth Rate Estimate	15.7

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	100
	9-Day RSI	99.99
	14-Day RSI	99.72
	3-1 Month Momentum %	1.32
	6-1 Month Momentum %	-2.73
	12-1 Month Momentum %	17.08

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.76
	Quick Ratio	2.33
	Cash Ratio	0.88
	Days Inventory	242.98
	Days Sales Outstanding	91.33
	Days Payable	25.06

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	4.5
	Shareholder Yield %	-3.41

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	82.79
	Operating Margin %	56.06
	Net Margin %	23.13
	EBITDA Margin %	41.36
	FCF Margin %	25.28
	OCF Margin %	44.76
	ROE %	109.88
	ROA %	14.95
	ROIC %	33.76
	3-Year ROIIC %	38.79
	ROC (Joel Greenblatt) %	95.32
	ROCE %	26.1
	Years of Profitability over Past 10-Year	7
	Moat Score	5
	Tariff Resilience Score	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	28.59
	Forward PE Ratio	9.38
	PE Ratio without NRI	21.77
	Shiller PE Ratio	56.82
	Price-to-Owner-Earnings	47.19
	PEG Ratio	0.6
	PS Ratio	6.47
	PB Ratio	42.89
	Price-to-Free-Cash-Flow	25.74
	Price-to-Operating-Cash-Flow	14.4
	EV-to-EBIT	21.53
	EV-to-EBITDA	18.03
	EV-to-Forward-EBITDA	9.81
	EV-to-Revenue	7.46
	EV-to-Forward-Revenue	6.42
	EV-to-FCF	29.61
	Price-to-GF-Value	0.82
	Price-to-Projected-FCF	2.02
	Price-to-Median-PS-Value	0.61
	Price-to-Peter-Lynch-Fair-Value	0.87
	Earnings Yield (Greenblatt) %	4.64
	FCF Yield %	4.03
	Forward Rate of Return (Yacktman) %	23.46

Financials (Next Earnings Date:2026-08-05 Est.)

Annual Quarterly TTM

MEX:HALO's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Halozyme Therapeutics Inc Executives

Details

GF Value™: MXN1622.53

MEX:HALO

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with HALO. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil MXN)	27,599.574
	EPS (TTM) (MXN)	51.716
	Beta	0.115
	3-Year Sharpe Ratio	0.55
	3-Year Sortino Ratio	4
	Volatility %	17.31
	14-Day RSI	99.72
	14-Day ATR (MXN)	6.640656
	20-Day SMA (MXN)	1234.268
	12-1 Month Momentum %	17.08
	52-Week Range (MXN)	1018.51 - 1395.66
	Shares Outstanding (Mil)	118.61

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Halozyme Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Halozyme Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (MXN)
Third quarter earnings conference call for 2026	2026-11-03 16:30	In 121 days
Third quarter earnings results for 2026	2026-11-03	In 120 days
Second quarter earnings conference call for 2026	2026-08-05 16:30	In 31 days
Second quarter earnings results for 2026	2026-08-05	In 30 days
First quarter earnings conference call for 2026	2026-05-11 16:30	1,177.00 (+0.00%)
First quarter earnings results for 2026	2026-05-11	1,177.00 (+0.00%)
General meeting for 2026	2026-05-05 09:00	1,177.00 (+0.00%)
The Citizens Life Sciences Conference	2026-03-11 11:20	1,200.00 (+0.00%)
Leerink Partners Global Healthcare Conference	2026-03-10 13:00	1,200.00 (+0.00%)
TD Cowen 46th Annual Healthcare Conference	2026-03-03 11:10	1,191.93 (+0.00%)

Show

Entries

Halozyme Therapeutics Inc Frequently Asked Questions

What is Halozyme Therapeutics Inc(MEX:HALO)'s stock price today?

The current price of MEX:HALO is MXN1327.00. The 52 week high of MEX:HALO is MXN1395.66 and 52 week low is MXN1018.51.

When is next earnings date of Halozyme Therapeutics Inc(MEX:HALO)?

The next earnings date of Halozyme Therapeutics Inc(MEX:HALO) is 2026-08-05 Est..

Does Halozyme Therapeutics Inc(MEX:HALO) pay dividends? If so, how much?

Halozyme Therapeutics Inc(MEX:HALO) does not pay dividend.

Press Release

	Subject	Date
	Halozyme Appoints David Ramsay as President Drug Delivery	2026-06-30
	Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029	2026-06-15
	Halozyme to Report First Quarter 2026 Financial and Operating Results	2026-04-30
	Halozyme Appoints Darren Snellgrove as Chief Financial Officer	2026-04-30
	Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology	2026-04-07
	Halozyme Appoints David Ramsay as Interim Chief Financial Officer	2026-03-12
	U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma	2026-03-06
	Halozyme to Participate in Upcoming Investor Conferences	2026-02-25
	HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE	2026-02-17
	Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results	2026-02-10

10/Page

Articles on Halozyme Therapeutics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.